一般描述
Cap B solution, containing tetrahydrofuran (THF), pyridine and N-methylimidazole (NMI), is mixed in situ with Cap A solution during the capping (acetylation) reaction. Pyridine is applied as a mild base while NMI provides a powerful acylation catalyst.Tetrahydrofurane has been replaced by acetonitrile in ÄKTA Cap B1 and B2.Cap B is configured for ÄKTA formulation.
制备说明
Acetonitrile / Pyridine 4/6 (v/v)
其他说明
Cap B2 solution, containing acetonitrile (ACN) and pyridine, is mixed in situ with Cap A and Cap B1 solution during the capping (acetylation) reaction.
Pyridine is applied as a mild base while NMI provides a powerful acylation catalyst.
Pyridine is applied as a mild base while NMI provides a powerful acylation catalyst.
法律信息
OligoPilot is a registered trademark of Cytiva
ÄKTA is a registered trademark of Cytiva
警示用语：
Danger
危险分类
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2 - Skin Irrit. 2
WGK
WGK 2
闪点(°F)
62.6 °F
闪点(°C)
17 °C
法规信息
危险化学品
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门